Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

Dr Tanios Bekaii-Saab reviews data from the MOUNTAINEER trial on combination tucatinib/trastuzumab in patients with HER2-positive metastatic colorectal cancer.

Video Player is loading.
Current Time 0:00
Duration 15:47
Loaded: 0%
Stream Type LIVE
Remaining Time 15:47
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

x